Editas Medicine, Inc. (EDIT) financial statements (2022 and earlier)

Company profile

Business Address 11 HURLEY ST.
CAMBRIDGE, MA 02141
State of Incorp. DE
Fiscal Year End December 31
SIC 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments500402457369329185
Cash and cash equivalents204140238135147185
Short-term investments296262219234183 
Restricted cash and investments4422  
Receivables060010
Prepaid expense   322
Other undisclosed current assets375110
Total current assets:507419464375332187
Noncurrent Assets
Operating lease, right-of-use asset262529
Property, plant and equipment171411403940
Long-term investments and receivables120110    
Long-term investments120110    
Other noncurrent assets755522
Total noncurrent assets:17015445464142
TOTAL ASSETS:677573509420373229
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities253028181522
Accounts payable566545
Accrued liabilities202422131117
Deferred revenue112124
Debt  6   
Deferred revenue and credits13 
Contract with customer, liability16
Other liabilities  3211
Other undisclosed current liabilities107  810
Total current liabilities:475860363733
Noncurrent Liabilities
Long-term debt and lease obligation161923323335
Capital lease obligations323335
Operating lease, liability161923
Liabilities, other than long-term debt611011631169526
Deferred revenue and credits9526
Accounts payable and accrued liabilities     0
Deferred revenue6174163
Contract with customer, liability116
Other liabilities 280000
Total noncurrent liabilities:7712118614812861
Total liabilities:12417924618416595
Stockholders' equity
Stockholders' equity attributable to parent554394262236208135
Common stock000000
Additional paid in capital1,4121,059812652514320
Accumulated other comprehensive income (loss)(0)(0)0(0)(0) 
Accumulated deficit(858)(665)(549)(416)(306)(186)
Total stockholders' equity:554394262236208135
TOTAL LIABILITIES AND EQUITY:677573509420373229

Income statement (P&L) ($ in millions)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
Revenues26912132146
Revenue, net146
Gross profit:26912132146
Operating expenses(219)(226)(161)(146)(134)(103)
Operating loss:(193)(135)(141)(114)(120)(97)
Nonoperating income (expense)11974(0)0
Investment income, nonoperating2373(1)0
Other nonoperating income (expense)(2)16(0)01(0)
Net loss attributable to parent:(193)(116)(134)(110)(120)(97)
Preferred stock dividends and other adjustments     (0)
Net loss available to common stockholders, basic:(193)(116)(134)(110)(120)(97)
Other undisclosed net income available to common stockholders, diluted1     
Net loss available to common stockholders, diluted:(191)(116)(134)(110)(120)(97)

Comprehensive Income ($ in millions)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
Net loss:(193)(116)(134)(110)(120)(97)
Other comprehensive income (loss)(0)(0)00(0) 
Comprehensive loss, net of tax, attributable to parent:(193)(116)(134)(110)(120)(97)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: